CV Sciences (OTC: CVSI) focuses on developing and commercializing novel therapeutics utilizing synthetic Cannabidiol (CBD). The company operates through two segments, Specialty Pharmaceutical and Consumer Product. It also manufactures, markets and sells plant-based CBD products under PlusCBD brand for a range of market sectors, including nutraceutical, beauty care, specialty foods and vape. The company’s Pharmaceutical Division is developing synthetically formulated cannabidiol‐based medicine, pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient. CV Sciences has achieved promising preclinical results in the development of cannabinoid medicines for treatment of a range of medical conditions. For more information, visit the company’s website at www.cvsciences.com.
HempWire (HW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, HW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.
For more information, visit https://www.hempwire.com
Please see full disclaimers on the HempWire website: http://nnw.fm/Disclaimer